Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge.
J W Georgitis, E O Meltzer, M Kaliner, J Weiler, R Berkowitz
Index: Ann. Allergy Asthma Immunol. 84(4) , 451-9, (2000)
Full Text: HTML
Abstract
Medications containing a combination antihistamine-decongestant are commonly used for allergic rhinitis yet onset-of-action comparisons for symptom relief after a single dose have not been performed.To determine the onset of symptom relief and efficacy of antihistamine-decongestant medications (acrivastine-pseudoephedrine and loratadine-pseudoephedrine) compared with placebo in an outdoor park.This study was conducted during the spring of 1997 using a double-blind, placebo-controlled design. Patients completed baseline rhinitis symptom diaries from 7:30 to 9:30 AM. Subjects with qualifying symptom scores received one dose of either acrivastine-pseudoephedrine, loratadine-pseudoephedrine, or placebo at 10:00 AM. Symptom diaries were recorded for the next 4 hours.Of 593 patients randomized to treatment, 592 were included in efficacy analysis. Acrivastine-pseudoephedrine and loratadine-pseudoephedrine demonstrated a mean onset-of-action by 45 and 30 minutes respectively for total symptom and rhinitis symptom scores for the five sites. Onset-of-action for nasal congestion scores was 45 minutes for both medications. Sites having higher pollen exposure (>100 pollen grains over 6 hours) demonstrated a difference between the antihistamine combinations: acrivastine-pseudoephedrine had an onset of action at 45 minutes for total symptom and rhinitis symptom scores, and 15 minutes for nasal congestion scores whereas loratadine-pseudoephedrine had onset-of-action for nasal congestion score of 105 minutes but failed to reach significance at any timepoint for total symptom and rhinitis symptom scores.Both antihistamine-decongestant combinations demonstrate an onset-of-action within 60 minutes of administration but under conditions of higher pollen exposure, the acrivastine combination was more effective for total symptoms, rhinitis symptoms, and nasal congestion with an onset-of-action within 45 minutes for rhinitis symptoms and 15 minutes for congestion.
Related Compounds
Related Articles:
Identification of novel functional inhibitors of acid sphingomyelinase.
2011-01-01
[PLoS ONE 6 , e23852, (2011)]
2005-04-01
[J. Pharm. Biomed. Anal. 37(4) , 663-7, (2005)]
1996-05-01
[Ann. Allergy Asthma Immunol. 76(5) , 432-8, (1996)]
2007-01-04
[J. Pharm. Biomed. Anal. 43(1) , 293-7, (2007)]
2004-01-01
[Drug Dev. Ind. Pharm. 30(10) , 1009-17, (2004)]